Project description:Investigation of expression differences induced by expression of the histone methyltransferase SETDB1 in human melanoma short-term culture WM451-Lu. A six-chip study using total RNA prepared from WM451-Lu melanoma short-term cultures infected with either a lentivirus encoding GFP (control) or SETDB1. Cells were allowed to grow for 2 days post-infection.
Project description:Investigation of expression differences induced by expression of the histone methyltransferase SETDB1 in human melanoma short-term culture WM451-Lu.
Project description:This SuperSeries is composed of the following subset Series: GSE17349: Expression data for melanoma short-term cultures and cell lines GSE17359: Affymetrix SNP array data for 3 melanoma short-term cultures and cell lines GSE20156: RNA-Seq of melanoma short-term cultures and cell lines Refer to individual Series
Project description:Melanoma cell isolated from melanoma tumors were cultured for less than 20 passages. RNAs were extracted and analysed on Agilent One-Color Gene Expression arrays
Project description:We profiled the gene expression levels from 8 melanoma short-term cultures and 1 melanoma cell line in order to compare to expression level estimates obtained by RNA-seq.
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets
Project description:The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets